Uh, and I think probably the first clinical indications are gonna be for patients with chronic conditions if it, if it pans out for like irrit, irritable bowel syndrome, Crohn's, uh, Marissa Liza: and that was sort of the non-athlete, the total healthcare provider part of me that was really interested in this
Improving metabolic conditions An estimated 75% of people with obesity have nonalcoholic fatty liver disease and 34% have MASH, or metabolic dysfunction-associated steatohepatitis, according to researchers with the German drugmaker Boehringer Ingelheim
However, these in vitro and animal studies lack validation in human SLE patients, and the optimal butyrate concentration for clinical application remains undetermined
Importantly, AOD-9604 does not bind to growth hormone receptors, which is why it lacks the glucose-elevating and IGF-1-stimulating effects of full-length growth hormone